Table 2.
Adherence of patients’ management to EULAR 2008 recommendations in the non‐endemic Middle‐European area
| Recommendations with short versions | Evidence | n | Conformitya | Comments |
|---|---|---|---|---|
| 1. Uveitis posterior: AZ A+CS | Ib | 0 | — | |
| 2. Severe eye involvement: CyA/IFX + AZA + CS | Ib/IIb | 2 | 100% | MMF used instead of AZA |
| 3. Vascular involvement: DVT – immunosuppression, arterial aneurysms – CyPh + CS | III | 11 | 81.8% | |
| 1 | 0% | |||
| 4. Vascular involvement: lack of evidence for anticoagulation | IV | 15 | Not included | Lacks further conclusions |
| 5. Gastrointestinal involvement: immunosuppression before surgery | III | 14 | 92.9% | |
| 6. Joint involvement: colchicine considered effective in most patients | Ib | 24 | 91.7% | More effective IS accepted |
| 7. Neurological involvement: parenchymal disease – CS, IFN, AZA, CyPh, MTX, αTNF; SVT – CS | III | 3 | 100% | |
| 8. Neurological involvement: cave CyA, except for urgent eye involvement | III | 16 | 100% | |
| 9. Skin and mucosal lesions: topic treatment (± CS) before colchicine, AZA, IFN, αTNF | Ib | 70 | OA: 95.7% | Depends on type of lesion |
| 15 | Acne: 93.3% | |||
| 17 | EN: 94.1% | |||
| 1 | IS last: 100% |
a
Evidence is described according to EULAR.8 Conformity with guidelines, organ‐specific treatment or better alternatives accepted. AZA, azathioprine; CS, corticosteroid; CyA, cyclosporin A; CyPh, cyclophosphamide; DVT, deep vein thrombosis; EN, erythema nodosum; EULAR, European League Against Rheumatism; IFN, interferon; IFX, infliximab; IS, immunosuppressives; MMF, mycophenolate mofetil; n, number of evaluable patients; OA, oral aphthae; SVT, sinus vein thrombosis; TNF, TNF‐blockers.